title: Secondary Neoplasms in Children with Hodgkin's Lymphoma Receiving C-MOPP and Radiotherapy: Presentation of Four Cases.
abstract: Patients who survive Hodgkin lymphoma (HL) are at increased risk of secondary neoplasms (SNs). A wide variety of SNs have been reported, including leukemias, non-Hodgkin's lymphomas, and solid tumors, specifically breast and thyroid cancers. Herein we report subsequent neoplasms in four patients with HL receiving chemoradiotherapy. It is interesting that three SNs, fibrosarcoma, thyroid carcinoma, and retrobulbar meningioma, were observed in the radiation area in one of our patients. A hypopharyngeal epithelioid malignant peripheral nerve sheath tumor as an unusual secondary malignant neoplasm developed in another patient, while a benign thyroid nodule and invasive ductal breast carcinoma were observed at different times in the female patient. Follicular adenoma of the thyroid gland developed in one of our patients.
authors.affiliation: Kemer Sk. No: 21/78 Büyükesat, Ankara, Turkey. E-mail: sgozdasoglu@hotmail.com.
authors.forename: Sevgi
authors.initials: S
authors.lastname: Gözdaşoğlu
authors.forename: Ali
authors.initials: A
authors.lastname: Pamir
authors.forename: Emel
authors.initials: E
authors.lastname: Ünal
authors.forename: İsmail Haluk
authors.initials: İH
authors.lastname: Gökçora
authors.forename: Ömer
authors.initials: Ö
authors.lastname: Uluoğlu
authors.forename: Koray
authors.initials: K
authors.lastname: Ceyhan
authors.forename: Haluk
authors.initials: H
authors.lastname: Deda
authors.forename: Erdoğan
authors.initials: E
authors.lastname: Işıkman
authors.forename: Gülsan
authors.initials: G
authors.lastname: Yavuz
authors.forename: Nurdan
authors.initials: N
authors.lastname: Taçyıldız
authors.forename: Ayhan
authors.initials: A
authors.lastname: Çavdar
mesh_terms: D000236:Adenoma / Q000209:etiology; D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000209:etiology; D018270:Carcinoma, Ductal, Breast / Q000209:etiology; D002291:Carcinoma, Papillary / Q000209:etiology; D059248:Chemoradiotherapy / Q000009:adverse effects*; D002648:Child; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D017809:Fatal Outcome; D005260:Female; D005354:Fibrosarcoma / Q000209:etiology; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000209:etiology; D015994:Incidence; D008297:Male; D008577:Meningeal Neoplasms / Q000209:etiology; D008579:Meningioma / Q000209:etiology; D009381:Neoplasms, Radiation-Induced / Q000453:epidemiology / Q000209:etiology* / Q000628:therapy; D016609:Neoplasms, Second Primary / Q000139:chemically induced / Q000453:epidemiology / Q000209:etiology*; D009442:Neurilemmoma / Q000209:etiology; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D011344:Procarbazine / Q000008:administration & dosage / Q000009:adverse effects; D012008:Recurrence; D016879:Salvage Therapy / Q000009:adverse effects; D013964:Thyroid Neoplasms / Q000209:etiology; D016606:Thyroid Nodule / Q000209:etiology; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D011344:Procarbazine; D014750:Vincristine; D003520:Cyclophosphamide; D011241:Prednisone